2 terminated, 1 not yet recruiting, 1 recruiting, 1 withdrawn. 3 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Not yet recruiting 1 |
| Phase 2 | 3 | Terminated 2, Recruiting 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Jennifer Amengual: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia Rituximab - PTLD, Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Jennifer Amengual | 28 | 2026-12-01 | 2026-09-17 |
| Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) Rituximab, Etoposide, Prednisone - Lymphoma, Lymphoma, B-Cell | Phase 2 | Recruiting | Jennifer Amengual | 30 | 2025-04-14 | 2026-05-27 |
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Romidepsin, Pralatrexate - Lymphoma, T-Cell, Peripheral | Phase 3 | Withdrawn | Jennifer Amengual | 2018-09-01 | 2018-12-19 | |
| ACY-1215 for Relapsed/Refractory Lymphoid Malignancies ACY-1215 - Lymphoma, Lymphoid Malignancies | Phase 1 / Phase 2 | Terminated | Jennifer Amengual | 23 | 2014-04-02 | 2024-08-06 |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Pralatrexate, Romidepsin - Lymphoid Malignancies, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Jennifer Amengual | 57 | 2013-09-09 | 2026-09-16 |
Lymphoma (3) · Lymphoma, Mantle-Cell (2) · Lymphoma, T-Cell, Peripheral (2) · Burkitt Lymphoma (1) · Epstein-Barr Virus Infections (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Infections (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Non-Hodgkin (1)
10-propargyl-10-deazaaminopterin (2) · Rituximab (2) · romidepsin (2) · Biological Assay (1) · Cyclophosphamide (1) · Doxorubicin (1) · Etoposide (1) · Prednisone (1) · Vincristine (1) · etoposide phosphate (1) · ricolinostat (1)
United States (3)